Lucid Diagnostics (LUCD) CEO On Going Public Last Week

<p>Lucid Diagnostics (LUCD) went public via an IPO on October 14th and opened at $12.75 per share. CEO Dr. Lishan Aklog says that the commercial stage medical diagnostics technology company is focused on patients with gastroesophageal reflux disease or GERD. What is next for LUCD and how will the stock continue to perform? Tune in for the full interview.</p><p><br></p>